September 7, 2016
Theravance Biopharma Highlights Positive Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva at ERS International Congress
September 2, 2016
Theravance Biopharma Announces New Employment Inducement Awards
September 1, 2016
Theravance Biopharma to Present at the Baird 2016 Global Healthcare Conference
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: